These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 23428534

  • 1. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
    Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
    [Abstract] [Full Text] [Related]

  • 2. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
    [Abstract] [Full Text] [Related]

  • 3. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3012-9. PubMed ID: 23720216
    [Abstract] [Full Text] [Related]

  • 4. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan 15; 32(1):48.e1-8. PubMed ID: 24055428
    [Abstract] [Full Text] [Related]

  • 5. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3020-6. PubMed ID: 23720197
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC, Hsu CH, Huang CY, Tsai YC, Huang KH, Cheng AL, Pu YS.
    Urology; 2007 Mar 15; 69(3):479-84. PubMed ID: 17382149
    [Abstract] [Full Text] [Related]

  • 7. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C, Agerbaek M, Von Der Maase H.
    Acta Oncol; 2009 Mar 15; 48(3):411-7. PubMed ID: 18798018
    [Abstract] [Full Text] [Related]

  • 8. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
    Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su HY.
    Oncology; 2020 Mar 15; 98(3):146-153. PubMed ID: 31794969
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY, Kwon WA, Cho IC, Kim EK, Park S, Yoon H, Seo HK, Chung J, Park WS, Lee KH.
    Int J Urol; 2011 May 15; 18(5):350-7. PubMed ID: 21355894
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    J Clin Oncol; 2004 Jan 15; 22(2):220-8. PubMed ID: 14665607
    [Abstract] [Full Text] [Related]

  • 11. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA.
    J Clin Oncol; 2004 Jan 15; 22(2):262-8. PubMed ID: 14722034
    [Abstract] [Full Text] [Related]

  • 12. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.
    Clin Genitourin Cancer; 2011 Sep 15; 9(1):27-30. PubMed ID: 21700509
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, Ohta H, Miyanishi K, Sato T, Takimoto R, Kobune M, Yamaguchi K, Hirata K, Niitsu Y, Kato J.
    Cancer Chemother Pharmacol; 2010 Sep 15; 66(4):721-8. PubMed ID: 20041328
    [Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Takahashi S, Suzuki M, Kume H, Matsumoto S, Okamoto N, Nishimatsu H, Tomita K, Kitamura T.
    Jpn J Clin Oncol; 2005 Feb 15; 35(2):79-83. PubMed ID: 15709091
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
    Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Kassouf W.
    Urol Oncol; 2014 Jan 15; 32(1):31.e17-24. PubMed ID: 23428535
    [Abstract] [Full Text] [Related]

  • 16. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ, Ou XQ, Chen ZB, Liao H, Peng YL, Wang SY, Zhang HY, Lin Z.
    Cancer Chemother Pharmacol; 2013 Aug 15; 72(2):323-8. PubMed ID: 23728706
    [Abstract] [Full Text] [Related]

  • 17. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP, Fossella F.
    Cancer; 2005 Dec 15; 104(12):2766-74. PubMed ID: 16288485
    [Abstract] [Full Text] [Related]

  • 18. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators.
    Eur Urol; 2017 Feb 15; 71(2):281-289. PubMed ID: 27726966
    [Abstract] [Full Text] [Related]

  • 19. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
    Sengeløv L, Kamby C, Geertsen P, Andersen LJ, von der Maase H.
    Cancer Chemother Pharmacol; 2000 Feb 15; 46(5):357-64. PubMed ID: 11127939
    [Abstract] [Full Text] [Related]

  • 20. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G.
    Clin Genitourin Cancer; 2013 Dec 15; 11(4):495-500. PubMed ID: 23800847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.